^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab

Published date:
02/17/2021
Excerpt:
Importantly, patients harbored STK11/KEAP1 mutations had a relatively worse OS than wild type both in those receiving atezolizumab and docetaxel (all, P < 0.05). 
Secondary therapy:
docetaxel
DOI:
10.1016/j.lungcan.2021.02.010
Evidence Level:
Resistant: C3 – Early Trials
Title:

P75.02 - Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy

Published date:
01/12/2021
Excerpt:
...we found that non-squamous NSCLC patients harbored STK11 or KEAP1 mutations had worse OS no matter treated with atezolizumab monotherapy or docetaxel (all, P < 0.001)….Non-squamous NSCLC patients harbored STK11 or KEAP1 mutation were not sensitive to any treatment, suggesting they may be a special subtype.